Aquestive Therapeutics Inc (AQST)
5.15
-0.37
(-6.70%)
USD |
NASDAQ |
Nov 04, 16:00
5.05
-0.10
(-1.94%)
Pre-Market: 08:37
Aquestive Therapeutics Enterprise Value: 409.12M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 409.12M |
| November 01, 2024 | 442.81M |
| October 31, 2024 | 440.08M |
| October 30, 2024 | 453.74M |
| October 29, 2024 | 455.56M |
| October 28, 2024 | 440.08M |
| October 25, 2024 | 440.08M |
| October 24, 2024 | 439.17M |
| October 23, 2024 | 429.15M |
| October 22, 2024 | 404.56M |
| October 21, 2024 | 390.91M |
| October 18, 2024 | 398.19M |
| October 17, 2024 | 388.17M |
| October 16, 2024 | 389.08M |
| October 15, 2024 | 385.44M |
| October 14, 2024 | 380.89M |
| October 11, 2024 | 385.44M |
| October 10, 2024 | 368.14M |
| October 09, 2024 | 373.60M |
| October 08, 2024 | 387.72M |
| October 07, 2024 | 381.80M |
| October 04, 2024 | 390.91M |
| October 03, 2024 | 366.32M |
| October 02, 2024 | 376.34M |
| October 01, 2024 | 373.60M |
| Date | Value |
|---|---|
| September 30, 2024 | 393.64M |
| September 27, 2024 | 369.96M |
| September 26, 2024 | 395.46M |
| September 25, 2024 | 382.71M |
| September 24, 2024 | 399.10M |
| September 23, 2024 | 384.53M |
| September 20, 2024 | 403.65M |
| September 19, 2024 | 413.67M |
| September 18, 2024 | 390.91M |
| September 17, 2024 | 376.34M |
| September 16, 2024 | 391.82M |
| September 13, 2024 | 380.89M |
| September 12, 2024 | 354.48M |
| September 11, 2024 | 390.91M |
| September 10, 2024 | 359.95M |
| September 09, 2024 | 367.23M |
| September 06, 2024 | 320.79M |
| September 05, 2024 | 325.34M |
| September 04, 2024 | 326.25M |
| September 03, 2024 | 321.70M |
| August 30, 2024 | 352.66M |
| August 29, 2024 | 340.82M |
| August 28, 2024 | 354.48M |
| August 27, 2024 | 361.77M |
| August 26, 2024 | 345.38M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
62.73M
Minimum
Mar 16 2020
455.56M
Maximum
Oct 29 2024
173.87M
Average
158.54M
Median
Jan 04 2024
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals Inc | 1.924B |
| Rockwell Medical Inc | 117.81M |
| Cormedix Inc | 535.86M |
| Geovax Labs Inc | 8.055M |
| Myomo Inc | 106.78M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.745M |
| Revenue (Quarterly) | 20.10M |
| Total Expenses (Quarterly) | 20.04M |
| EPS Diluted (Quarterly) | -0.03 |
| Gross Profit Margin (Quarterly) | 77.48% |
| Profit Margin (Quarterly) | -13.66% |
| Earnings Yield | -7.07% |
| Normalized Earnings Yield | -6.835 |